文献速递乳腺癌

SET2,3指数联合RS评分在淋巴结阳性乳腺癌中的独立验证

Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial.
PubMed 文献 · Eur J Cancer · 2025-12-01

本研究基于PACS-01试验中659例激素受体阳性、淋巴结阳性乳腺癌患者的肿瘤样本,检测RS与SET2,3指数,评估两者联合对8年远处无复发生存间期(DRFI)的预后价值。多变量分析显示SET2,3状态在RS状态之上提供显著预后信息,两者状态不一致者占27%,SETER/PR组分可预测内分泌治疗对DRFI的效应。

要点

  • SET2,3状态在RS评分基础上提供独立预后信息,二者联合可优化风险分层。
  • SET2,3与RS状态不一致者占27%,该组8年DRFI差异显著。
  • SETER/PR指数可预测内分泌治疗对DRFI的效应(交互P<0.001)。

核心结论

  • 在HR+、LN+乳腺癌中,SET2,3指数改善了RS评分的预后评估,其SETER/PR组分在接受内分泌治疗的患者中为RS增加了显著的内分泌预测信息。

研究设计与样本

  • 基于PACS-01试验的HR+肿瘤样本检测RS与SET2,3指数,预设切点定义高危为RS>25或SET2,3<2.10。
  • RS与SET2,3结果可用的患者共659例,其中490例接受了内分泌治疗。
  • 主要分析评估接受内分泌治疗患者的8年远处无复发生存间期(DRFI),采用多变量Cox比例风险模型计算风险比(HR,95%CI),双侧检验,名义显著性p<0.05。

主要发现

  • 主要多变量分析显示SET2,3状态在RS状态之上增加显著预后信息(SET2,3:HR 0.29,95%CI 0.18-0.47;RS:HR 2.62,95%CI 1.62-4.25)。
  • SET2,3与RS状态在27%的患者中不一致。
  • 不一致患者中,高危RS但高SET2,3者8年DRFI率高出22%(80.5% versus 58.5%)。
  • 不一致患者中,低危RS但低SET2,3者8年DRFI率低17.2%(77.3% versus 94.5%)。
  • SETER/PR指数预测内分泌治疗对DRFI的效应(交互作用P<0.001),并在内分泌治疗亚组中为RS增加预后信息(SETER/PR:HR 0.58,95%CI 0.36-0.91)。

关键数值与推荐

  • 预设高危切点:RS>25或SET2,3<2.10。
  • SET2,3:HR 0.29,95%CI 0.18-0.47;RS:HR 2.62,95%CI 1.62-4.25(主要多变量分析)。
  • SETER/PR:HR 0.58,95%CI 0.36-0.91(内分泌治疗亚组);交互作用P<0.001。

临床怎么用

  • 对HR+、LN+乳腺癌患者,可在RS评分基础上联合SET2,3指数以细化预后评估。
  • 对RS与SET2,3状态不一致的患者,SET2,3结果有助于识别实际预后偏离RS预测的亚群。
  • SETER/PR指数可用于辅助判断内分泌治疗对DRFI的预期获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To independently confirm whether the combination of sensitivity to endocrine therapy (SET2,3) index and Recurrence Score® (RS) improves prognostic assessment for patients with hormone receptor-positive (HR+) lymph node-positive (LN+) breast cancer. Secondly, to evaluate SETER/PR index, the component of SET2,3 that measures endocrine transcriptional activity. METHODS: HR+ tumor samples from the PACS-01 trial were tested for RS and SET2,3 index. Pre-defined cut points defined high-risk if RS > 25 or SET2,3 < 2.10. The primary analysis assessed 8-year distant recurrence-free interval (DRFI) in patients who received endocrine therapy (ET). Hazard ratios were calculated with 95 % confidence interval (HR, 95 %CI) from multivariable Cox proportional hazards models, with two-sided tests and nominal significance at p < 0.05. RESULTS: RS and SET2,3 results were available from 659 patients including 490 who received ET. Primary multivariable analysis showed that SET2,3 status added significant prognostic information to RS status (SET2,3: HR 0.29, 95 %CI 0.18-0.47; RS: HR 2.62, 1.62-4.25). SET2,3 and RS status were discordant in 27 % of patients. Among those, DRFI rate at 8 years was 22 % higher in patients with high SET2,3 despite high-risk RS (80.5 % versus 58.5 %), and 17.2 % lower with low SET2,3 despite low-risk RS (77.3 % versus 94.5 %). The SETER/PR index predicted the ET effect on DRFI (Pinteraction <0.001) and added prognostic information to RS in ET subset (SETER/PR: HR 0.58, 95 %CI 0.36-0.91). CONCLUSION: SET2,3 improved prognostic assessment by RS, with its SETER/PR index component adding significant endocrine-predictive information to RS in the patients who received ET. TRIAL REGISTRATION: PACS-01.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Penault-Llorca F, Lusque A, Filleron T, et al. Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial. Eur J Cancer. 2025. PMID: 41411882. doi:10.1016/j.ejca.2025.116152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。